2026-04-29T04:09:25Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/164062024-09-27T08:50:31Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc García-Culebras, Alicia author Cuartero, María Isabel author Peña-Martínez, Carolina author Moraga, Ana author Vázquez-Reyes, Sandra author de Castro-Millán, Francisco Javier author Cortes-Canteli, Marta author Lizasoain, Ignacio author Moro, María Ángeles author 2023-06-07 Growing evidence supports the suggestion that the peripheral immune system plays a role in different pathologies associated with cognitive impairment, such as vascular dementia (VD) or Alzheimer's disease (AD). The aim of this review is to summarize, within the peripheral immune system, the implications of different types of myeloid cells in AD and VD, with a special focus on post-stroke cognitive impairment and dementia (PSCID). We will review the contributions of the myeloid lineage, from peripheral cells (neutrophils, platelets, monocytes and monocyte-derived macrophages) to central nervous system (CNS)-associated cells (perivascular macrophages and microglia). Finally, we will evaluate different potential strategies for pharmacological modulation of pathological processes mediated by myeloid cell subsets, with an emphasis on neutrophils, their interaction with platelets and the process of immunothrombosis that triggers neutrophil-dependent capillary stall and hypoperfusion, as possible effector mechanisms that may pave the way to novel therapeutic avenues to stop dementia, the epidemic of our time. Br J Pharmacol. 2023 Jun 7. http://hdl.handle.net/20.500.12105/16406 37282844 10.1111/bph.16159 1476-5381 British journal of pharmacology Myeloid cells in vascular dementia and Alzheimer's disease: Possible therapeutic targets?